NDAORALTABLET
Approved
Oct 2002
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
DAYPRO ALTA (oxaprozin potassium) by Pfizer is analgesic, anti-inflammatory, and antipyretic properties. First approved in 2002.
Drug data last refreshed 17h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DAYPRO ALTA is an oral NSAID containing oxaprozin potassium, a COX-1/COX-2 inhibitor approved for pain and inflammation management. It works by inhibiting prostaglandin synthesis to reduce pain, fever, and inflammatory symptoms. The potassium salt formulation enables faster onset compared to standard oxaprozin.
LOE Approaching
As LOE approaches, commercial teams face declining market exclusivity; expect restructuring toward managed care and generic transition strategies rather than growth initiatives.
Mechanism of Action
analgesic, anti-inflammatory, and antipyretic properties. The mechanism of action of oxaprozin, like that of other NSAIDs, is not completely understood but involves inhibition of cyclooxygenase (COX-1 and COX-2). Oxaprozin is a potent inhibitor of prostaglandin synthesis in vitro. Oxaprozin…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on DAYPRO ALTA offers limited career growth due to LOE status and minimal market differentiation; roles emphasize operational efficiency, payer relations, and defensive positioning rather than innovation or expansion. Professionals should expect restructuring, smaller team sizes, and transition planning as generic competition intensifies.
Brand Manager
Worked on DAYPRO ALTA at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.